Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: A subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

Gastric Cancer

Volumn 15, Issue 3, 2012, Pages 313-322

  Sawaki, Akira ^a,b   Ohashi, Yasuo ^c   Omuro, Yasushi ^d   Satoh, Taroh ^e   Hamamoto, Yasuo ^f   Boku, Narikazu ^g   Miyata, Yoshinori ^h   Takiuchi, Hiroya ⁱ   Yamaguchi, Kensei ^j   Sasaki, Yasutsuna ^k   Nishina, Tomohiro ^l   Satoh, Atsushi ^m   Baba, Eishi ⁿ   Tamura, Takao ^o   Abe, Takashi ^p   Hatake, Kiyohiko ^q   Ohtsu, Atsushi ^r  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c Nishiyama Kogyo Ochanomizu Building 5F   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOCHIGI CANCER CENTER   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

ⁱ OSAKA MEDICAL COLLEGE   (Japan)

^j SAITAMA CANCER CENTER   (Japan)

^k SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^m SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ KYUSHU UNIVERSITY HOSPITAL   (Japan)

^o KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p Yamagata Prefectural Central Hospital   (Japan)

^q CANCER INSTITUTE HOSPITAL   (Japan)

^r NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

more..

Author keywords

Drug therapy; Randomized controlled trial; Stomach neoplasms; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; CANCER PROGNOSIS; CONSTIPATION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; EPISTAXIS; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; HAND FOOT SYNDROME; HEART FAILURE; HICCUP; HUMAN; HYPERPIGMENTATION; HYPERTENSION; INDUCED HYPOTHERMIA; INSOMNIA; JAPANESE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; PRIORITY JOURNAL; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CISPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84865429022     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0118-1     Document Type: Article

References (19)

1. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2010. Available from http://ganjoho.ncc.go.jp/public/statistics/backnumber/2010- en.html. Accessed 30 June 2011.
2. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
3. Hudis CA. Trastuzumab\mechanism of action and use in clin-ical practice. N Engl J Med. 2007;357:39-51.
4. Bang Y-J, Chung HC, Xu JM, Lordick F, Sawaki A, Lipatov O, et al. Pathological features of advanced gastric cancer: relation-ship to human epidermal growth factor receptor 2 positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27:abstract 4556.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesopha-geal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687-97.
7. Tsuburaya A, Narahara H, Imamura H, Hatake K, Imamoto H, Esaki T, et al. GC0301/TOP002 Study Group. Updated result on the 2.5-year follow-up of GC0301/TOP-002: randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol. 2009;27:abstract 4544.
8. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Gastrointestinal Oncology Study Group of the Japan Clin-ical Oncology Group. Fluorouracil versus combination of irino-tecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol. 2009;10:1063-9.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Cons-tenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
10. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagoga-stric cancer. N Engl J Med. 2008;358:36-46.
11. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256-64.
12. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer che-motherapy between the East and West. J Clin Oncol. 2006;24: 2188-96.
13. Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A. Gastric Cancer Working Group report. Jpn J Clin Oncol. 2010;40(Suppl 1):i28-37.
14. Warneke VS, Behrens H-M, Hartmann JT, Held H, Becker T, Schwarz NT, et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29:2364-71.
15. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395-403.
16. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol. 2004;34:654-9.
17. Adachi Y, Yoshida K, Inomata M, Sato K, Shiraishi N, Kitano S, et al. Pathology and prognosis of gastric carcinoma. Well versus poorly differentiated type. Cancer. 2000;89:1418-24.
18. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. Japan Clinical Oncology Group. D2 lymphade-nectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
19. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, et al. Combination chemotherapy with capecitabine (X) and cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol. 2007;37:30-7.